Table 1.
Open in new tab

Demographics of study population

Demographic parameterPatientsHealthy donors
Age, yr31–7131–59
Female4 (40)7 (64)
Total number of study subjects1011
Induction ISRabbit ATG, methylprednisoloneN/A
Viral prophylaxisValganciclovir (Valcyte)N/A
Demographic parameterPatientsHealthy donors
Age, yr31–7131–59
Female4 (40)7 (64)
Total number of study subjects1011
Induction ISRabbit ATG, methylprednisoloneN/A
Viral prophylaxisValganciclovir (Valcyte)N/A

Values are range, n (%), or n.

Abbreviations: IS, immunosuppression; N/A, not applicable.

Table 1.
Open in new tab

Demographics of study population

Demographic parameterPatientsHealthy donors
Age, yr31–7131–59
Female4 (40)7 (64)
Total number of study subjects1011
Induction ISRabbit ATG, methylprednisoloneN/A
Viral prophylaxisValganciclovir (Valcyte)N/A
Demographic parameterPatientsHealthy donors
Age, yr31–7131–59
Female4 (40)7 (64)
Total number of study subjects1011
Induction ISRabbit ATG, methylprednisoloneN/A
Viral prophylaxisValganciclovir (Valcyte)N/A

Values are range, n (%), or n.

Abbreviations: IS, immunosuppression; N/A, not applicable.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close